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S U M M A R Y
Objectives: To evaluate the prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster
virus (VZV) disease after allogeneic hematopoietic stem cell transplantation (HSCT).
Methods: We evaluated 141 patients who were planned to receive acyclovir at 200 mg/day until the end
of immunosuppressive therapy and for at least 1 year after HSCT in our center between June 2007 and
June 2012.
Results: The cumulative incidence of VZV disease after HSCT was 4.5% at 1 year and 18.3% at 2 years.
Protocol violation was the only independent signiﬁcant factor that increased the incidence of VZV
disease (hazard ratio (HR) 7.50, 95% conﬁdence interval (CI) 3.60–15.63). Excluding patients with
protocol violation, the discontinuation of acyclovir was the only signiﬁcant factor for the development of
VZV disease (HR 5.90, 95% CI 1.56–22.37). Six patients experienced breakthrough VZV disease, but four of
these six had not taken acyclovir for several weeks before breakthrough VZV disease. On the other hand,
the cumulative incidence of VZV disease after the cessation of acyclovir was 28.4% at 1 year and 38.0% at
2 years. The proportion of disseminated VZV disease was only 7% and no patient died directly of VZV
disease.
Conclusions: This study shows that long-term ultra-low-dose acyclovir appears to be effective for
preventing VZV disease, especially disseminated VZV disease, after allogeneic HSCT. We recommend
continuing acyclovir until the end of immunosuppressive therapy and for at least 1 year after HSCT, but
additional strategies such as the administration of varicella vaccine may be needed to eradicate VZV
disease.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Varicella zoster virus (VZV) disease is a common complication
after hematopoietic stem cell transplantation (HSCT), with a
relatively high incidence of more than 20%.1–4 Although a localized
dermatomal rash is the major clinical presentation, disseminated
VZV disease occasionally occurs and may result in a fatal outcome.3
In addition, several complications, such as post-herpetic neuralgia* Corresponding author. Tel.: +81 48 647 2111; fax: +81 48 644 8167.
E-mail address: ycanda-tky@umin.ac.jp (Y. Kanda).
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http://dx.doi.org/10.1016/j.ijid.2013.09.020and secondary bacterial infections, are occasionally observed,1,4
and may impair the patient’s quality of life. Therefore, to reduce
VZV disease and its complications, the long-term administration of
acyclovir has been evaluated in several studies.
From the mid-1980s to the mid-2000s, several studies
concluded that the overall cumulative incidence of VZV disease
was not decreased by prophylactic acyclovir at 600–3200 mg/day
for a ﬁxed period of up to 6 months or 1 year, because of the
increase in VZV disease after the cessation of long-term acyclovir,
although VZV disease was almost completely suppressed during
prophylaxis.5–8 Therefore, the Centers for Disease Control and
Prevention/Infectious Diseases Society of America/American Soci-
ety for Blood and Marrow Transplantation (CDC/IDSA/ASBMT)
guidelines of 2000 did not recommend universal long-term
acyclovir prophylaxis to prevent VZV disease.9 However, a largeciety for Infectious Diseases. Open access under CC BY-NC-ND license.
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reduced VZV disease, which was further decreased by the
continuation of prophylaxis in patients who remained on
immunosuppressive drugs.10 Furthermore, we have previously
reported that a lower dose of acyclovir at 200–400 mg/day could
also reduce VZV disease.11,12 Another clinical beneﬁt of long-term
acyclovir is the reduction of disseminated VZV disease and its
complications.10,12,13 Therefore, long-term acyclovir prophylaxis is
routinely recommended for the ﬁrst year after HSCT in the 2009
guidelines that were co-sponsored by several international
groups.14
However, the optimal duration of prophylaxis, the minimal
effective dose, and the risk factors for VZV disease after cessation
remain unclear. In the present study, the clinical courses of
patients who were planned to receive acyclovir at 200 mg/day
until the end of immunosuppressive therapy and for at least 1 year
after HSCT were analyzed retrospectively. First we identiﬁed risk
factors predictive for the development of VZV disease. In particular,
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Figure 1. Flow diagram of 1factor or not. Next, we assessed the causal effect of acyclovir use/
non-use, excluding patients with protocol violation.
2. Patients and methods
2.1. Patients
The clinical charts of 161 consecutive patients who underwent
their ﬁrst allogeneic HSCT between June 2007 and June 2012 at our
institution were reviewed retrospectively. Among these patients,
20 were excluded: 14 died within 35 days after HSCT, ﬁve failed to
achieve complete remission after HSCT, and one experienced graft
rejection and early recovery of host-derived hematopoiesis after
HSCT. Thus, 141 patients were included in this study (Figure 1). We
followed up 102 patients until the last observation (censored
observation) or the development of VZV disease, 32 patients until
death without VZV disease, and seven patients until second
transplantation without VZV disease. The clinical and epidemio-
logical characteristics of the patients are shown in Table 1. This(n=20)
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Table 1
Patient characteristics
Characteristics
Median age, years (range) 45 (15–65)
Sex, n (%)
Male 83 (58.9%)
Female 58 (41.1%)
Disease, n (%)
AML 67 (47.5%)
ALL 14 (9.9%)
MPAL 2 (1.4%)
CML 3 (2.1%)
MDS 16 (11.4%)
NHL/ATL 23 (16.3%)
SAA 12 (8.5%)
Others 4 (2.8%)
Disease risk, n (%)
Standard 111 (78.7%)
High 30 (21.3%)
Donor, n (%)
Related 56 (39.7%)
Unrelated 85 (60.3%)
HLA (antigen) compatibility, n (%)a
Matched 107 (75.9%)
Mismatched 34 (24.1%)
HLA (allele) compatibility, n (%)a
Matched 81 (57.5%)
Mismatched 48 (34.0%)
Uncertain/missing 12 (8.5%)
Graft source, n (%)
Bone marrow 73 (58.9%)
Peripheral blood 47 (33.3%)
Cord blood 11 (7.8%)
Conditioning regimen, n (%)
Myeloablative 81 (57.4%)
Reduced-intensity 60 (42.6%)
GVHD prophylaxis, n (%)
Cyclosporine-based 126 (89.4%)
Tacrolimus-based 15 (10.6%)
Use of ATG/alemtuzumab, n (%)
Yes 19 (13.5%)
No 122 (86.5%)
Acute GVHD, n (%)
Grade 0–I 90 (63.8%)
Grade II–IV 51 (36.2%)
Acute GVHD, n (%)
Grade 0–II 124 (87.9%)
Grade III–IV 17 (12.1%)
Chronic GVHD, n (%)
Extensive 38 (26.9%)
Limited 21 (14.9%)
None 73 (51.8%)
Not evaluable 9 (6.4%)
VZV seropositivity, n (%)
Positive 135 (95.7%)
Negative 1 (0.7%)
Not examined 5 (3.6%)
AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MPAL,
mixed phenotype acute leukemia; CML, chronic myelogenous leukemia; MDS,
myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; ATL, adult T-cell
leukemia/lymphoma; SAA, severe aplastic anemia; HLA, human leukocyte antigen;
GVHD, graft-versus-host disease; ATG, antithymocyte globulin; VZV, varicella
zoster virus.
a HLA compatibility was deﬁned according to HLA-A, HLA-B, and HLA-DR loci.
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tional Review Board of Saitama Medical Center, Jichi Medical
University.
2.2. Transplantation procedure
The myeloablative conditioning regimen was mainly a combi-
nation of cyclophosphamide (60 mg/kg for 2 days) with either total
body irradiation (TBI; 2 Gy twice daily for 3 days) or busulfan
(3.2 mg/kg/day for 4 days). The reduced-intensity conditioningregimen was a combination of ﬂudarabine with either busulfan or
melphalan, with or without low-dose TBI, for elderly or clinically
inﬁrm patients. The conditioning regimen for severe aplastic
anemia was a combination of ﬂudarabine, cyclophosphamide, and
anti-thymoglobulin, with or without TBI at 2 Gy. Alemtuzumab or
anti-thymoglobulin was added for patients who received a
haploidentical HSCT.15
Prophylaxis for graft-versus-host disease (GVHD) consisted of
cyclosporine or tacrolimus combined with short-term methotrex-
ate (10–15 mg/m2 on day 1, 7–10 mg/m2 on days 3 and 6, and an
optional dose on day 11). The target blood concentration of
calcineurin inhibitors was determined based on the disease risk.
Standard-risk diseases included acute leukemia in complete
remission, chronic myelogenous leukemia in the chronic phase,
myelodysplastic syndrome without leukemic transformation,
lymphoma in remission, and non-malignant disorders such as
aplastic anemia, while more advanced diseases were considered
high-risk diseases. Acute GVHD was graded as previously
described.16 Methylprednisolone or prednisolone at 1 mg/kg was
added for patients who developed grade II–IV acute GVHD.
Prophylaxis against bacterial, fungal, and Pneumocystis jirovecii
infection consisted of ﬂuoroquinolones, ﬂuconazole or itracona-
zole, and sulfamethoxazole/trimethoprim or inhalation of pent-
amidine, respectively. Pre-emptive therapy with ganciclovir or
valganciclovir for cytomegalovirus (CMV) infection was performed
by monitoring CMV antigenemia by the C10/11 method weekly
after engraftment. The initial doses of ganciclovir and valganci-
clovir were 5 mg/kg and 900 mg once daily, respectively.17 When
increasing antigenemia was observed, the doses were elevated to
5 mg/kg and 900 mg twice daily, respectively.
2.3. Prophylactic administration of acyclovir
As prophylaxis against herpes simplex virus (HSV) infection,
patients treated before August 2009 received oral acyclovir at
200 mg ﬁve times daily (ACV1000) from day 7 to 35, whereas
patients treated after September 2009 received oral acyclovir at
200 mg once daily (ACV200).18 When patients could not take
acyclovir orally, intravenous acyclovir at 250 mg once and twice
daily was administered instead of oral acyclovir in the ACV200 and
ACV1000 groups, respectively. In both groups, oral acyclovir was
principally continued at 200 mg once daily from day 36 to the end
of immunosuppressive therapy and for at least 1 year after HSCT to
prevent VZV disease. In the case of CMV infection or disease,
acyclovir was discontinued, while ganciclovir, valganciclovir, or
foscarnet was used for treatment.
2.4. Diagnosis and treatment of VZV disease
The diagnosis of VZV disease was made based on the presence of
characteristic vesicular skin lesions on an erythematous base
within a dermatome, or a generalized cutaneous distribution.
Microbiological, pathological, and/or serological conﬁrmation was
not performed routinely except in equivocal cases. Post-herpetic
neuralgia was deﬁned as dermatomal pain persisting beyond 1
month after the initial presentation of VZV disease. VZV disease
was treated with oral valacyclovir at 3000 mg/day, oral famciclovir
at 1500 mg/day, oral acyclovir at 4000 mg/day, or intravenous
acyclovir at 15–30 mg/kg/day for 7 days. In patients with renal
impairment, the doses of these drugs were adjusted according to
the creatinine clearance.
2.5. Statistical analysis
The cumulative incidence of VZV disease and the impact of
possible confounding factors on VZV disease were evaluated using
Figure 2. (A) Cumulative incidence of VZV disease after allogeneic HSCT in 141
patients who received acyclovir at 200 mg/day. (B) Cumulative incidence of VZV
disease after allogeneic HSCT in 130 patients in the protocol observance group
versus 11 patients in the protocol violation group.
Table 2
Risk factors for VZV disease after HSCT
Univariate analysis
Factors Subgroup n Incidence at
3 years, % (95% CI)
p-Value
Age <45 years 70 23.5 (13.1–35.7) 0.88
45 years 71 25.6 (14.1–38.7)
Sex Male 83 20.8 (11.3–32.2) 0.56
Female 58 29.7 (16.7–44.0)
Disease AML 67 20.9 (10.4–33.8) 0.96
ALL 14 29.9 (5.1–61.2)
MPAL 2 NAa
CML 3 33.3 (0.1–83.2)
MDS 16 15.5 (2.2–40.4)
NHL/ATL 23 29.6 (11.2–50.8)
SAA 12 34.4 (6.5–65.9)
Others 4 25.0 (0.3–71.4)
Disease risk Standard 111 19.7 (11.8–28.9) 0.13
High 30 42.6 (20.2–63.5)
Conditioning
regimen
Myeloablative 81 23.7 (13.8–35.1) 0.80
Reduced-
intensity
60 26.6 (13.7–41.4)
Donor Related 56 15.4 (6.6–27.6) 0.11
Unrelated 85 32.1 (20.0–44.8)
HLA (antigen)
compatibilityb
Matched 107 25.5 (16.3–35.6) 0.58
Mismatched 34 21.6 (7.2–40.9)
HLA (allele)
compatibilityb
Matched 81 24.0 (14.3–35.2) 0.92
Mismatched 48 25.5 (9.5–45.3)
Uncertain/
missing
12 27.8 (4.8–58.3)
Graft source Bone marrow 83 29.5 (18.6–41.3) 0.24
Peripheral blood 47 13.6 (4.7–27.1)
Cord blood 11 NAc
GVHD
prophylaxis
Cyclosporine-
based
126 23.4 (15.1–32.7) 0.16
Tacrolimus-
based
15 38.9 (9.4–68.5)
Use of ATG/
alemtuzumab
Yes 19 30.3 (8.6–56.0) 0.66
No 122 23.8 (15.4–33.3)
Protocol
violation
Yes 11 NAd <0.001
No 130 17.7 (10.7–26.3)
Multivariate analysis
Factor Hazard ratio 95% CI p-Value
Protocol violation 7.50 3.60–15.63 <0.001
VZV, varicella zoster virus; HSCT, hematopoietic stem cell transplantation; CI,
conﬁdence interval; AML, acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; MPAL, mixed phenotype acute leukemia; CML, chronic myelogenous
leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; ATL,
adult T-cell leukemia/lymphoma; SAA, severe aplastic anemia; NA, not available;
HLA, human leukocyte antigen; GVHD, graft-versus-host disease; ATG, antithy-
mocyte globulin.
a The cumulative incidence of VZV disease after transplantation was 0.0% (0.0–
0.0%) at 225 days.
b HLA compatibility was deﬁned according to HLA-A, HLA-B, and HLA-DR loci.
c The cumulative incidence of VZV disease after transplantation was 46.8% (0.4–
90.2%) at 929 days.
d The cumulative incidence of VZV disease after transplantation was 90.9% (0.0–
99.9%) at 964 days.
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second transplantation as competing risks.19 Multivariate analyses
for cumulative incidences were performed using Cox proportional
hazards regression modeling and Fine and Gray regression
modeling.20 In a multivariate analysis to identify risk factors
predictive for VZV disease, variables subjected to the model were
selected in a stepwise manner based on Akaike’s information
criterion (AIC). p-Values of less than 0.05 were considered
statistically signiﬁcant. All statistical analyses were performed
with EZR (Saitama Medical Center, Jichi Medical University),21
which is a graphical user interface for R (The R Foundation for
Statistical Computing, version 2.13.0). More precisely, it is a
modiﬁed version of R commander (version 1.6–3) that was
designed to add statistical functions that are frequently used in
biostatistics.
3. Results
3.1. Administration of prophylactic acyclovir
It was planned to administer oral acyclovir until the end of
immunosuppressive therapy and for at least 1 year after HSCT to
prevent VZV disease. However, acyclovir was prematurely
discontinued in 11 patients – at the request of the patient in
two cases, at the physician’s discretion in seven, and for reasons
that are unclear in two. These patients were regarded as the
‘protocol violation group’.3.2. Incidence and risk factors for VZV disease after HSCT
Overall, 28 of the 141 patients developed VZV disease at a
median of 486 days (range 90–1393 days) after HSCT. The
cumulative incidence of VZV disease after HSCT was 4.5% (95%
conﬁdence interval (CI) 1.8–8.9%) at 1 year and 18.3% (95% CI 11.8–
26.0%) at 2 years (Figure 2A). Six patients experienced break-
through VZV disease during long-term acyclovir, at days 90, 159,
165, 398, 420, and 459 after HSCT. However, four of these six
Table 3
Multivariate analysis treating the use of acyclovir as a time-dependent covariate,
excluding patients with protocol violation
Factor Hazard ratio 95% CI p-Value
Age 45 years 1.18 0.33–4.25 0.80
Sex: female 1.96 0.70–5.45 0.20
Disease risk: high 2.30 0.71–7.41 0.16
Conditioning regimen:
reduced-intensity
1.02 0.28–3.77 0.97
Donor: unrelated 0.89 0.16–5.16 0.90
HLA (antigen) compatibility:
mismatched
0.53 0.054–5.23 0.59
Graft source: peripheral blood 0.44 0.064–3.02 0.40
Graft source: cord blood 1.40 0.090–21.54 0.81
GVHD prophylaxis:
cyclosporine-based
0.69 0.14–3.44 0.65
Use of ATG/alemtuzumab 1.37 0.097–19.16 0.82
Discontinuation of acyclovir 5.90 1.56–22.37 <0.001
CI, conﬁdence interval; HLA, human leukocyte antigen; GVHD, graft-versus-host
disease; ATG, antithymocyte globulin.
Figure 3. Cumulative incidence of VZV disease after the cessation of long-term
acyclovir in 39 patients.
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breakthrough VZV disease due to poor compliance. The six patients
developed VZV disease in a limited dermatomal distribution and
responded promptly to a therapeutic dose of valacyclovir. In the
multivariate analysis of the whole population, protocol violation
was the only independent signiﬁcant factor that increased the
incidence of VZV disease (hazard ratio (HR) 7.50, 95% CI 3.60–
15.63, p < 0.001, Table 2, Figure 2B). Nine of the 11 patients who
were included in the protocol violation group developed VZV
disease at a median of 464 days (range 191–964 days) after HSCT.Table 4
Risk factors for VZV disease after the cessation of acyclovir
Univariate analysis
Factors Subgroup 
Age <40 years 
40 years 
Sex Male 
Female 
Disease risk Standard 
High 
Conditioning regimen Myeloablative 
Reduced-intensity 
Donor Related 
Unrelated 
HLA (antigen) compatibilitya Matched 
Mismatched 
HLA (allele) compatibilitya Matched 
Mismatched 
Uncertain/missing 
Graft source Bone marrow 
Peripheral blood 
Cord blood 
GVHD prophylaxis Cyclosporine-based 
Tacrolimus-based 
Duration of ACV prophylaxis <1.5 years 
1.5 years 
Lymphocyte count at the cessation of ACV <2  109/l 
2  109/l 
Chronic GVHD Yes 
No 
Duration of ACV prophylaxis after the cessation
of immunosuppressive drugs
<100 days 
100 days 
VZV, varicella zoster virus; HLA, human leukocyte antigen; NA, not available; GVHD, g
a HLA compatibility was deﬁned according to HLA-A, HLA-B, and HLA-DR loci.
b The cumulative incidence of VZV disease after the cessation of acyclovir was 31.4%
c The cumulative incidence of VZV disease after the cessation of acyclovir was 35.2%
d The cumulative incidence of VZV disease after the cessation of acyclovir was 50.0%
e The cumulative incidence of VZV disease after the cessation of acyclovir was 50.0%The cumulative incidence of VZV disease at 1 year and 2 years after
HSCT was 27.3% (95% CI 5.8–55.2%) and 54.5% (95% CI 20.6–79.2%),
respectively, in the protocol violation group, and 2.3% (95% CI 0.6–
6.1%) and 14.8% (95% CI 8.6–22.6%), respectively, in the protocol
observance group (p < 0.001, Figure 2B). Next, we performed an
analysis treating the use of acyclovir as a time-dependent
covariate, excluding patients with protocol violation. The discon-
tinuation of acyclovir was the only signiﬁcant factor for the
development of VZV disease (HR 5.90, 95% CI 1.56–22.37,
p < 0.001, Table 3).n Incidence at 2 years, % (95% CI) p-Value
20 12.9 (1.9–34.6) 0.0066
19 63.5 (26.2–85.7)
22 25.2 (8.8–45.9) 0.32
17 56.5 (16.9–83.3)
32 31.3 (13.2–51.5) 0.28
7 67.9 (9.8–93.7)
27 36.3 (15.7–57.5) 0.86
12 37.9 (10.0–66.4)
17 21.1 (4.6–45.7) 0.14
22 51.4 (21.8–74.8)
32 37.5 (18.8–56.3) 0.96
7 NAb
25 32.6 (17.8–55.0) 0.47
9 NAc
5 20.0 (0.4–63.2)
23 45.0 (21.4–66.1) 0.62
13 21.1 (2.5–51.7)
3 NAd
35 36.2 (17.8–55.0) 0.26
4 NAe
28 44.9 (21.8–65.6) 0.26
11 20.0 (2.6–49.0)
25 34.9 (15.9–54.7) 0.71
14 45.6 (7.3–79.0)
17 48.1 (13.3–76.7) 0.71
22 32.2 (12.2–54.4)
18 43.1 (15.3–68.6) 0.75
21 34.0 (11.2–58.8)
raft-versus-host disease; ACV, acyclovir; CI, conﬁdence interval.
 (3.0–68.3%) at 455 days.
 (6.7–66.8%) at 455 days.
 (0.0–96.0%) at 350 days.
 (2.3–88.1%) at 482 days.
Table 5
Clinical outcomes of VZV disease (n = 28)
Localized zoster, n (%) 26 (93%)
Trigeminal 4
Cervical 6
Thoracic 10
Lumbar 2
Sacral 4
Disseminated disease, n (%) 2 (7%)
Cutaneous 2
Visceral 1a
Meningoencephalitis 1b
Hospitalized, n (%)
Yes 2 (7%)
No 26 (93%)
Treatment, n (%)
Acyclovir IV 1 (3.5%)
Acyclovir PO 1 (3.5%)
Valacyclovir 24 (86%)
Famciclovir 1 (3.5%)
No treatment 1 (3.5%)
Complications, n (%)
Post-herpetic neuralgia 8 (29%)
Facial paralysis 1 (3.5%)
Neurologic symptoms 1 (3.5%)c
None 18 (64%)
VZV, varicella zoster virus; IV, intravenous; PO, by mouth.
a One patient had both disseminated cutaneous zoster and visceral involvement.
b One patient had both disseminated cutaneous zoster and meningoencephalitis.
c Neurologic symptoms, including paralysis in the left lower extremity, pain in
both legs, and rectal/bladder disorder, persisted in one patient who developed VZV
meningoencephalitis.
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acyclovir
Of the 141 patients who received long-term acyclovir, 50
discontinued acyclovir before the onset of VZV disease, death, or
second transplantation. We analyzed the incidence and risk factors
for VZV disease after the cessation of acyclovir in 39 of the 50
patients without protocol violation (Figure 1). The median duration
of acyclovir prophylaxis was 400 days (range 364–1230 days) and
the median follow-up duration after the cessation of acyclovir was
370 days (range 17–1347 days). Thirteen of the 39 patients
developed VZV disease at a median of 163 days (range 44–784
days) after the discontinuation of acyclovir. The cumulative
incidence of VZV disease after the cessation of acyclovir was
28.4% (95% CI 14.6–44.0%) at 1 year and 38.0% (95% CI 20.1–55.8%) at
2 years (Figure 3). In a univariate analysis, only age 40 years was
signiﬁcantly associated with a higher incidence of VZV disease
(Table 4).
3.4. Clinical outcomes of VZV disease after HSCT
Twenty-six of the 28 patients developed VZV disease in a
localized dermatomal distribution (Table 5). Localized zoster could
be treated successfully with oral antiviral agents without hospitali-
zation. The other two patients developed cutaneous disseminated
VZV disease at days 464 and 681 after HSCT and were hospitalized
for treatment. One of the two patients developed VZV meningoen-
cephalitis at 115 days after the cessation of acyclovir and was treated
with intravenous acyclovir at 30 mg/kg/day.22 The other patient had
abdominal pain with cutaneous disseminated VZV disease at 112
days after the cessation of acyclovir, and we considered it to be a
symptom of visceral involvement. Although no patient died directly
of VZV disease, complications after VZV disease were observed in 10
patients. Neurologic symptoms, including paralysis in the left lower
extremity, pain in both legs, and a rectal/bladder disorder, persisted
in one patient who developed VZV meningoencephalitis, while eightpatients developed post-herpetic neuralgia and the other developed
unilateral facial paralysis (Ramsay Hunt syndrome).
4. Discussion
This study demonstrated that the use of acyclovir at 200 mg/
day was associated with a low incidence of VZV disease after
allogeneic HSCT. On the other hand, a small number of patients
experienced breakthrough VZV disease during long-term acyclovir
and approximately 40% of patients developed VZV disease after the
discontinuation of acyclovir. In particular, patients who had not
taken acyclovir regularly due to poor compliance and who violated
the protocol more frequently developed VZV disease, although we
planned to administer oral acyclovir until the end of immunosup-
pressive therapy and for at least 1 year after HSCT. The cumulative
incidence of VZV disease after HSCT was signiﬁcantly higher in the
protocol violation group than in the protocol observance group.
These results suggest that the long-term administration of
acyclovir based on our protocol was highly effective for preventing
VZV disease.
However, the development of VZV disease after the cessation of
long-term acyclovir remains unresolved. In a univariate analysis,
only age 40 years was signiﬁcantly associated with a higher
incidence of VZV disease. However, this result might be somewhat
incidental. There was only one patient who restarted immunosup-
pressive agents, and therefore we could not analyze the effect of
the resumption of immunosuppressive therapy. Among previous
studies, Erard et al. demonstrated that late-onset VZV disease was
further decreased by extended prophylaxis beyond 1 year in
patients who remained on immunosuppressive drugs.10 The
ﬁnding of the current study – that protocol violation was
signiﬁcantly associated with a higher incidence of VZV disease –
is consistent with their conclusion. We cannot, however, ignore the
possibility that the increased incidence of VZV disease in protocol
violators was not because of the acyclovir discontinuation but
because acyclovir tended to be more frequently discontinued in
patients who were at higher risk for VZV disease. However, this is
less likely, since the major reason for protocol violation was
physician discretion, not based on the physical status of the
patient. Therefore, acyclovir prophylaxis should be continued for at
least as long as the immunosuppressive drugs are administered.
However, the development of VZV disease after the discontinua-
tion of acyclovir cannot be eliminated even by this strategy, and
immune reconstitution against VZV may be a more important
issue. Boeckh et al. demonstrated that there was no statistically
signiﬁcant difference in the reconstitution of VZV-speciﬁc T-cell
responses between patients who received acyclovir at 800 mg
twice daily and those who received placebo.8 This ﬁnding suggests
that subclinical VZV reactivation continues to occur during
prophylaxis and that this antigen exposure may boost immunity
and prevent subsequent symptomatic VZV disease.23,24 However,
additional strategies are required, since the natural reconstitution
of VZV-speciﬁc T-cell immunity after allogeneic HSCT was not
sufﬁcient to eradicate VZV disease. A possible strategy is to
administer VZV vaccine. Hata et al. demonstrated that inactivated
varicella vaccine signiﬁcantly reduced clinical VZV disease in
patients who underwent autologous HSCT.25 Although no data are
available on the effectiveness of inactivated varicella vaccine in
allogeneic HSCT recipients, several small retrospective studies
have reported that the live attenuated varicella vaccine is safe and
immunogenic,26,27 and recent vaccine guidelines permit the use of
a live attenuated varicella vaccine in selected patient groups.28
Prospective studies are necessary to evaluate the safety, efﬁcacy,
and immunogenicity of the varicella vaccine.
In this study, the incidence of disseminated VZV disease was
only 7% and no patient died directly of VZV disease, as found in
K. Kawamura et al. / International Journal of Infectious Diseases 19 (2014) 26–3232previous studies.10,12,13 An important beneﬁt of long-term
acyclovir prophylaxis may be the prevention of disseminated
VZV disease and its complications, although this study was too
small to show such a beneﬁt statistically. A delay in the onset of
VZV disease by long-term acyclovir prophylaxis allows VZV-
speciﬁc immune reconstitution, which results in a marked
decrease in disseminated VZV disease.
The minimal effective dose of long-term acyclovir also remains
unclear. In this study, acyclovir was administered at a dose of
200 mg, which is the minimal dose used in previous studies.5–
8,10,13 This dose was as effective at preventing VZV disease as
acyclovir at higher doses in previous studies (600–3200 mg/day),
and was superior in terms of low cost and drug compliance, since
only one dose was required per day. On the other hand, a major
concern regarding long-term ultra-low-dose acyclovir prophylaxis
is the emergence of resistant VZV strains. In this study, acyclovir-
resistant VZV was not observed, although there were six cases of
breakthrough localized zoster that responded well to a therapeutic
dose of valacyclovir. About 300 patients, including those in our
previous studies, have received long-term ultra-low-dose acyclovir
prophylaxis and have not developed clinically resistant VZV
disease.12 In addition, acyclovir-resistant HSV was not observed, as
described previously.18
In conclusion, this study shows that long-term ultra-low-dose
acyclovir appears to be effective for preventing VZV disease,
especially disseminated VZV disease, after allogeneic HSCT. The
incidence of VZV disease in patients who violated our protocol was
extremely high, and therefore we recommend continuing acyclovir
until the end of immunosuppressive therapy and for at least 1 year
after HSCT. However, additional strategies, such as the combina-
tion of long-term acyclovir prophylaxis and the administration of
varicella vaccine, may be needed to eradicate VZV disease.
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